Ralph Snyderman

CIK 1178031 · last filed 2025-05-29

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$13.97M

Companies

Total Filings

Lifetime Open-Market Net

-$2.19M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

CDNA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O SAIC
10260 CAMPUS POINT DR M/S F3
SAN DIEGO, CA 92121

Related Filers

PHARMACEUTICAL PRODUCT DEVELOPMENT INC — 3 joint filings, latest 2011-12-06

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
IRTC	Director	13,288	$88.86	$1.18M	-$97.9K	13	2025-05-29
CDNA	Director	58,177	$84.51	$4.92M	-$1.83M	44	2022-10-04
ARGOS THERAPEUTICS INC (ARGS) Delisted	Director	29	—	—	$0	2	2017-01-04
Press Ganey Holdings, Inc. (PGND) Delisted	Director	0	—	—	$0	3	2016-10-25
PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted	Director	0	—	—	$0	2	2011-12-06
PG	Director	46,690	$168.62	$7.87M	-$259.7K	14	2010-06-11

Recent Filings · Page 7 of 9

88 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2015-04-24	CDNA	Exer (M)	+11,678	$27.2K	EDGAR
2015-04-03	CDNA	Grant (A)	+1,440	$0	EDGAR
2015-01-05	CDNA	Grant (A)	+1,417	$0	EDGAR
2014-10-03	CDNA	Grant (A)	+543	$0	EDGAR
2014-07-23	CDNA	Grant (A)	—	$0	EDGAR
2012-06-08	—	Grant (A)	—	$0
2011-12-06	PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted	Disp (D)	−1,139	-$37.9K	EDGAR
2011-06-17	—	Grant (A)	—	$0
2011-05-19	PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted	Grant (A)	+1,139	$0	EDGAR
2010-06-18	—	Grant (A)	—	$0

Showing 61–70 of 88

Prev Page 7 of 9 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.